INTRODUCTION {#s1}
============

Head and neck cancer (HNC) is a group of biologically similar cancers originating from the oral cavity, nasopharyngeal, oropharynx, hypopharynx and larynx, which mainly behave as squamous cell carcinoma histologically. HNC is the sixth most frequent type of malignant tumor, causing more than 400,000 deaths annually worldwide \[[@R1]-[@R5]\]. Its high mortality rate and the disfigurement or functional deficiency that survivors may suffer result in a considerable global public health burden. Despite great advance in multidisciplinary combined diagnosis and treatment, only 30-50% patients with HNC survive over 5 years after initial diagnosis worldwide \[[@R6]\]. Clinically, the classic tumor, node, and metastasis (TNM) staging system is widely used for the initial diagnosis but failed to reflect the inherent biological heterogeneity especially in atypical early symptoms or concealed metastasis patients. Therefore, novel biomarkers involved in cancer development are greatly needed to stratify patients with poor prognosis of HNC in order to make optimal individualized therapy.

Much attention has been focused on the involvement of mucins (MUC) in tumor carcinogenesis and metastasis recently. MUC is a family of high O-glycosylated protein, characterized by a basic structure including a central polymorphic tandem repeat region \[[@R7]-[@R8]\]. Only expressing on the apical surfaces of various luminal and glandular normal epithelial cells, MUC play an important role in cell-cell adhesion, immune response and alteration of intracellular signaling \[[@R9]\]. However, the tightly regulated homeostatic expression may be disrupted by various factors such as cancer cells, in particular. The observation of subcellular distribution and biochemical features changes during malignant transformation and tumor progression suggest that MUC may be the key point in carcinogenesis and subsequent metastasis of cancers \[[@R10]-[@R14]\]. Therefore, aberrant MUC expression may be predictive biomarkers in HNC.

Over the past decade, numerous independent studies have evaluated the clinical and the prognostic value of MUC protein expression in HNC. Yet, the results of these reports remain controversial and no clear consensus has been achieved so far \[[@R15]-[@R19]\]. Limited to small sample size some publications may draw inconsistent results due to potential random errors. Therefore, we conducted a systematic review and meta-analysis to address the association between MUC expression and prognostic value and the common clinicopathological parameters of HNC.

RESULTS {#s2}
=======

Eligible studies {#s2_1}
----------------

A total of 655 potential relevant studies were retrieved after the primary database searches and two additional studies were obtained from the reference lists. After careful screening of the titles and abstracts, 609 articles were excluded as shown in Figure [1](#F1){ref-type="fig"}. Then eventual 48 publications underwent elaborately full-text evaluation. Eventually, 20 observational studies consisting of 2064 cases were satisfied for subsequent pooling calculation \[[@R15]-[@R19], [@R26]-[@R40]\].

![Flow diagram of the study selection process](oncotarget-08-96359-g001){#F1}

Demographic characteristics of included studies {#s2_2}
-----------------------------------------------

Altogether, the sample-size ranged from 28 to 357, with a median of 103.2 participants. The median age of patients in all studies was 55.6 years old (range, 42.3-66.3) and the mean proportion of male patients was about 52.9%. The matching criteria varied among the enrolled studies. Studies concerning MEC and PTC occupied the largest proportion of cancer types among all primary literatures (*n* = 5, respectively), followed by HNSCC (*n* = 4), OSCC (*n* = 3) and remaining types of solid neoplasm. The MUC1 and MUC4 expression were evaluated by IHC staining in paraffin-embedded tissue blocks using several monoclonal antibodies as DF3, Ma695, VU4H5 for MUC1 and 1G8, 8G7, 15H10 for MUC4 respectively. As for the clinicopathological factors, seventeen eligible studies were divided into seven subgroups: 5 for age, 11 for gender, 10 for TNM tumor stage, 11 for tumor size, 13 for lymph node metastasis, 12 for tumor differentiation and 6 for mode of invasion. With respect to the quality of the including studies, none of the eligible entries scored less than six stars by the Newcastle-Ottawa Scale system, indicating a relative high methodological quality across all studies. Other detailed information were extracted and summarized in Table [1](#T1){ref-type="table"}.

###### Characteristics of eligible studies included in the meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
       First\         Year   Country     Case Number\                   Cancer\      Mean\     Male/\    AT\*    Method   Ab used        Expression\                  Cutoff    C.\             Prognosis   Analysis\   NOS\*\*\
       Author                            (positive rate)                Type         age       Female                                    Location                               Features^\#^                Method      Score
  ---- -------------- ------ ----------- ------------------------------ ------------ --------- --------- ------- -------- -------------- ---------------------------- --------- --------------- ----------- ----------- ----------
  1    Nitta T        2000   Japan       77\                            OSCC         NA        NA        No      IHC      DF3\           Membranes and/\              5%        D,T,N,S,I       NA          NA          8
                                         (59.7%)                                                                          /-             or cytoplasm                                                                   

  2    Alos L         2005   Spain       40\                            MEC          53.0      18/22     AR/AC   IHC      Ma695\         membranes and cytoplasm      5%        D               sur.\       M           8
                                         (100%/\                                                                          / Polyclonal                                                          curve                   
                                         95%)                                                                                                                                                                           

  3    Handra LA      2005   France      63\                            MEC          52.2      20/43     NA      IHC      Ma695\         membranes and/or cytoplasm   Median    P               sur.\       M           8
                                         (71%/\                                                                           /1G8                                                                  curve                   
                                         79%)                                                                                                                                                                           

  4    Wreesmann VB   2004   USA         74\                            PTC          NA        28/46     No      IHC      VU4H5\         membranes and cytoplasm      Score≥2   NA              HR          M           7
                                         (31%)                                                                            /-                                                                                            

  5    Hamada T       2012   Japan       206\                           OSCC         66.3      133/73    No      IHC      DF3\           membranes and/ cytoplasm     5%        G,D,T,N,S,P,I   HR          U/M         8
                                         (39%)                                                                            /-                                                                                            

  6    Cros J         2013   France      114\                           MSGT         52+18     NA        AR/AC   IHC      Polyclonal\    cytoplasm                    Score≥2   NA              HR          U           8
                                         (26.3%)                                                                          /-                                                                                            

  7    Macha MA       2016   USA         87\                            HNSCC        59.5      61/25     NA      IHC      -/\            cytoplasm                    Score≥1   G,D,N,S         NA          NA          8
                                         (78%)                                                                            8G7                                                                                           

  8    Morari EC      2010   Brazil      289\                           PTC and FC   NA        NA        NA      IHC      VU4H5\         cytoplasm                    Score≥3   G,T,S,A,I       NA          NA          7
                                         (75.8%)                                                                          /-                                                                                            

  9    Baek SK        2007   Korea       87\                            PTC          48.6      15/72     NA      IHC      VU4H5\         membranes and/or cytoplasm   Score≥3   G,T,N,S,A,I     NA          NA          8
                                         (72%)                                                                            /1G8                                                                                          

  10   Croce MV       2008   Argentina   125\                           HNSCC        59.9      98/27     NA      IHC      CT33\          membranes and/or cytoplasm   Median    G,D,T,N,S       NA          NA          7
                                         (80%)                                                                            /-                                                                                            

  11   LI X           2005   China       59\                            HC           58.2      48/11     No      IHC      NA             membranes and cytoplasm      50%       D,N,S           NA          NA          6
                                         (66.1%)                                                                                                                                                                        

  12   Siyi L         2014   China       62\                            MEC          56.2      48/14     No      IHC      Nov lab\       membranes and/or cytoplasm   25%       G,T,N,P         HR          M           8
                                         (92%)                                                                            /-                                                                                            

  13   Renaud F       2014   France      94\                            PTC          42.3      23/71     NA      IHC      M8\            membranes and/or cytoplasm   20%       G,N,A,I         sur.\       M           8
                                         (49%)                                                                            /-                                                                    curve                   

  14   Liu S          2014   China       357\                           MEC          45.9      162/195   No      IHC      Nov lab\       membranes and/or cytoplasm   25%       G,D,T,P         HR          M           8
                                         (69%)                                                                            /-                                                                                            

  15   Paleri V       2004   UK          30\                            LSCC         66.0      NA        AR      ISH      NA             Nucleus\                     Score≥1   NA              HR          M           6
                                         (43%)                                                                                           and/or\                                                                        
                                                                                                                                         cytoplasm                                                                      

  16   Hamada T       2012   Japan       150\                           OSCC         64.5      97/53     No      IHC      -/\            membranes and/or cytoplasm   5%        G,D,N,S,T,I     HR          U/M         8
                                         (41%)                                                                            8G7                                                                                           

  17   He F           2009   China       53\                            PTC          50±11/\   16/37     No      IHC      DF3\           membranes and/or cytoplasm   25%       G,N,A,S         NA          NA          7
                                         (57%)                                       45±12                                /-                                                                                            

  18   Weed DT        2001   USA         40\                            HNSCC        61        NA        No      IHC      -/\            membranes and/or cytoplasm   10%       D,T,N,S         NA          NA          7
                                         (85%)                                                                            15H10                                                                                         

  19   Weed DT        2004   USA         28\                            MEC          54.3      11/17     No      IHC      -/\            membranes and/or cytoplasm   30%       D               sur.\       M           7
                                         (54% for 1G8, 79% for 15H10)                                                     1G8, 15H10                                                            curve                   

  20   Croce MV       2001   UK          29\                            HNSCC        58.1      23/6      No      IHC      C595\          membranes and/or cytoplasm   Median    S,N,T,G,A       NA          NA          8
                                         (69%)                                                                            /-                                                                                            
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*AT: Adjuvant therapy; ^\#^C. Features: clinicopathological features; AR: adjuvant radiotherapy; AC: adjuvant chemotherapy; NA: not available

\*\*NOS: Newcastle-Ottawa Scale; Sur. curve: survival curve; IHC: immunohistochemistry; ISH: in situ hybridization

HR: hazard ratio; A: age; G:gender; T: TNM stage; D: differention; S: tumor size; N: lymph node metastasis; P: perineural invasion; I: mode of invasion

OSCC: oral squamous cell carcinoma; MEC: mucoepidermoid carcinoma; PTC: papillary carcinoma; MSGT: malignant tumors of the salivary glands

FC: follicular carcinoma; HNSCC: head and neck suqamous cell carcinoma; HC: hypopharyngeal carcinoma; LSCC: laryngeal squamous cell carcinoma

Impact of MUC expression on survival rates of patients in HNC {#s2_3}
-------------------------------------------------------------

Seven observational trials including 993 participants offered original data on survival rates in terms of different MUC expression (Table [2](#T2){ref-type="table"}). It demonstrated that increased MUC activity was associated with unfavorable survival rate (HR = 1.83, 95%CI: 1.43-2.33, *P* \< 0.001). There was no significant heterogeneity among these studies (I^2^ = 0.0%, *p* (Q-test) = 0.577), so that a fixed-effect model was used to combine the HR and 95% CI (Figure [2](#F2){ref-type="fig"}).

###### Results of overall and subgroup analyses for effects of MUC expression on overall survival in head and neck cancer

  Categories            Study N.   Samples   Pooled data        Test of heterogeneity                  
  --------------------- ---------- --------- ------------------ ----------------------- ------ ------- ------
  OS                    7          993       1.83 (1.43-2.33)   0.000                   4.74   0.577   0.0
  Nationality                                                                                          
   Asia                 4          775       1.92 (1.46-2.52)   0.000                   1.95   0.583   0
   Western countries    3          218       1.50 (0.88-2.57)   0.140                   2.14   0.343   6.5
  Cancer type                                                                                          
  Salivary tumors       3          533       2.04 (1.36-3.07)   0.001                   2.22   0.329   10
  Non-salivary tumors   4          460       1.72 (1.27-2.33)   0.000                   2.07   0.557   0
  Adjuvant therapy                                                                                     
   AR and/or AC         2          144       1.06 (0.51-2.19)   0.874                   0.17   0.677   0
   Non-AT               5          849       1.96 (1.51-2.53)   0                       2.12   0.714   0
  Sample size                                                                                          
   \> 100               4          827       1.76 (1.34-2.31)   0                       1.78   0.62    0
   \< 100               3          166       2.12 (1.25-3.61)   0.006                   2.59   0.275   22.6
  Methods                                                                                              
   IHC                  6          963       1.88 (1.47-2.41)   0                       3.29   0.656   0
   ISH                  1          30        0.85 (0.24-3.02)   0.802                   0.00   ---     ---
  Cut-off value                                                                                        
   \>10%                5          607       1.95 (1.38-2.77)   0                       4.08   0.395   2
   \<10%                2          386       1.72 (1.22-2.41)   0.002                   0.39   0.535   0
  MUC subtype                                                                                          
   MUC1                 5          813       2.09 (1.51-2.89)   0                       2.29   0.683   0
   MUC4                 2          180       1.53 (1.06-2.22)   0.023                   0.91   0.341   0
  Tumor location                                                                                       
   OSCC                 2          356       1.72 (1.22-2.41)   0.002                   0.39   0.535   0
   LSCC                 1          30        0.85 (0.24-3.02)   0.802                   0.00   ---     ---
  Antibody for MUC1                                                                                    
   DF3                  3          625       2.28 (1.55-3.36)   0                       0.42   0.812   0
   Others               2          188       1.70 (0.94-3.06)   0.081                   1.2    0.273   16.7
  Antibody for MUC4                                                                                    
   8G7                  1          150       1.62 (1.12-2.41)   0.014                   0.00   ---     ---
   Others               1          30        0.85 (0.24-3.02)   0.802                   0.00   ---     ---

![Funnel plot of hazard ratios (HR) for overall survival associated with high level of MUC expression](oncotarget-08-96359-g002){#F2}

Furthermore, subgroup analysis stratified by nationality, cancer type, adjuvant therapy, sample size, methods, cut-off value, MUC subtype, tumor location, antibody for MUC1 and antibody for MUC4 were performed respectively.

With regard to nationality, a worse survival rate was strongly linked to MUC positivity in Asian patients (*n* = 4, HR = 1.92, 95% CI: 1.46-2.52, *p* = 0.000, I^2^ = 0.0%), while over-expression of MUC in western countries was irrelevant with poor prognosis (*n* = 3, HR = 1.50, 95% CI: 0.88-2.57, *p* = 0.140, I^2^ = 6.5%).

In the subgroup analysis by cancer type, a worse survival rate was strongly linked to MUC positivity in salivary tumors (*n* = 3, HR = 2.04, 95% CI: 1.36-3.07, *p* = 0.001, I^2^ = 10.0%) than in non-salivary tumors (*n* = 4, HR = 1.72, 95% CI: 1.27-2.33, *p* = 0.000, I^2^ = 0.0%).

As to adjuvant therapy (AT) and surgery operation, elevated MUC expression was referred to a worse prognostic role in non-AT (*n* = 5, HR = 1.96, 95% CI: 1.51-2.53, *p* = 0.000, I^2^ = 0.0%). Nevertheless, higher MUC activity was irrelevant with AT (*n* = 2, HR = 1.06, 95% CI: 0.51-2.19, *p* = 0.874, I^2^ = 0.0%).

In the subgroup analysis by sample size, higher MUC expression status was significantly associated with poorer survival rate both in sample size \> 100 group (*n* = 4, HR = 1.76, 95% CI: 1.34-2.31, *p* = 0.000, I^2^ = 0.0%) and sample size \< 100 group (*n* = 3, HR = 2.12, 95% CI: 1.25-3.61, *p* = 0.006, I^2^ = 22.6%).

There were two stratified subgroup in terms of detecting method among papers. Higher MUC expression was related to poorer survival rate according to IHC method (*n* = 6, HR = 1.88, 95% CI: 1.47-2.41, *p* = 0.000, I^2^ = 0.0%), but not to ISH method (*n* = 1, HR = 0.85, 95% CI: 0.24-3.02, *p* = 0.802).

Subgroups analysis by different cut-off values indicating that high MUC expression was associated to a worse prognosis no matter in cut-off \> 10% (*n* = 5, HR = 1.95, 95% CI: 1.38-2.77, *p* = 0.000, I^2^ = 2.0%) or cut-off \< 10% (*n* = 2, HR = 1.72, 95% CI: 1.22-2.41, *p* = 0.002, I^2^ = 0.0%).

Stratified by MUC subtype of the included papers, MUC1 positive status was identified as a worse prognosis marker in HNC (*n* = 5, HR = 2.09, 95% CI: 1.51-2.89, *p* = 0.000, I^2^ = 0.0%) than MUC4 (*n* = 2, HR = 1.53, 95% CI: 1.06-2.22, *p* = 0.023, I^2^ = 0.0%).

With regard to the tumor location, higher MUC expression was related to poorer survival rate in oral squamous cell carcinoma (OSCC) (*n* = 2, HR = 1.72, 95% CI: 1.22-2.41, *p* = 0.002, I2 = 0.0%), but not in laryngeal squamous cell carcinoma (LSCC) (*n* = 1, HR = 0.85, 95% CI: 0.24-3.02, *p* = 0.802).

As for the type of antibody used for detecting MUC1 specificity, a worse survival rate was strongly linked to DF3 antibody (*n* = 3, HR = 2.28, 95% CI: 1.55-3.36, *p* = 0.000, I^2^ = 0.0%), while over-expressions of MUC1 detected by other antibodies were irrelevant with poor prognosis (*n* = 2, HR = 1.70, 95% CI: 0.94-3.06, *p* = 0.081, I^2^ = 16.7%).

Similarly, elevated MUC4 expression was referred to a worse prognostic role detected by 8G7 antibody (*n* = 1, HR = 1.62, 95% CI: 1.12-2.41, *p* = 0.014), but not by other antibody (*n* = 1, HR = 0.85, 95% CI: 0.24-3.02, *p* = 0.802).

Correlation of MUC expression with clinicopathological parameters {#s2_4}
-----------------------------------------------------------------

We also investigated the association of high MUC expression and clinicopathological features. As reported in Table [3](#T3){ref-type="table"}, higher MUC expression was significantly associated with more advanced TNM stage (I+II *vs*.III+IV, *n* = 10, RR = 0.84, 95% CI: 0.73-0.97, *p* = 0.017, Figure [3C](#F3){ref-type="fig"}), lymph node metastasis (negative *vs*. positive, *n* = 13, RR = 0.69, 95% CI: 0.57-0.84, *p* = 0.000, Figure [3E](#F3){ref-type="fig"}), and mode of invasion (1 to 3 *vs*. 4c + 4d, *n* = 6, RR = 0.58, 95% CI: 0.44-0.76, *p* = 0.000, Figure [3F](#F3){ref-type="fig"}). However, MUC over-expression was not significantly associated with gender (male *vs*. female, *n* = 11, RR = 0.98, 95% CI: 0.90-1.08, *p* = 0.707), age ( \< 45 yr *vs*. \> 45 yr, *n* = 5, RR = 0.91, 95% CI: 0.75-1.09, *p* = 0.304), grade of differentiation (well + moderate *vs*. poor, *n* = 12, RR = 1.16, 95% CI: 0.98-1.37, *p* = 0.075) and tumor size (T1 + T2 *vs*. T3 + T4, *n* = 11, RR = 0.90, 95% CI: 0.75-1.07, *p* = 0.236).

###### Meta-analysis of the association between MUC expression and clinicopathological features of head and neck cancer

  Clinicopathological variables              Study N.   Samples          Stat.   Pooled data         Test of heterogeneity                   
  ------------------------------------------ ---------- ---------------- ------- ------------------- ----------------------- ------- ------- ------
  Gender (male/female)                                                                                                                       
  All studies                                11         1502 (726/776)   FEM     0.98 (0.90-1.08 )   0.707                   9,52    0.392   6.2
  Subgroup                                                                                                                                   
    MUC1                                     8          1266 (568/698)   FEM     0.98 (0.89-1.08)    0.676                   8.53    0.272   0.0
    MUC4                                     2          236 (158/78)     FEM     1.00 (0.79-1.28)    0.993                   0.86    0.443   0.0
  Age (\<45 yr / \>45 yr)                                                                                                                    
  All studies                                5          514 (239/275)    FEM     0.91 (0.75-1.09)    0.304                   0.12    0.998   0.0
  Subgroup                                                                                                                                   
    MUC1                                     5          514 (239/275)    FEM     0.91 (0.75-1.09)    0.304                   0.12    0.998   0.0
   MUC4                                      0          ---              ---     ---                 ---                     ---     ---     ---
  UICC stage (I+II/ III+IV)                                                                                                                  
  All studies                                10         1296(806/490)    REM     0.84 (0.73-0.97)    0.017                   26.76   0.002   66.4
  Subgroup                                                                                                                                   
   MUC1                                      9          1146(702/444)    REM     0.87 (0.76-1.00)    0.052                   20.2    0.010   60.4
   MUC4                                      1          150(104/46)      REM     0.56 (0.39-0.80)    0.002                   0.00    ---     ---
  Differentiation (well + moderate / poor)                                                                                                   
  All studies                                12         1233(902/331)    REM     1.16 (0.98-1.37)    0.075                   21.89   0.025   49.7
  Subgroup                                                                                                                                   
   MUC1                                      9          961(690/271)     REM     1.12 (0.90-1.38)    0.272                   19.74   0.011   59.5
   MUC4                                      3          272(212/60)      REM     1.23 (0.96-1.58)    0.099                   2.06    0.357   2.90
  Lymph node (with / without metastasis)                                                                                                     
  All studies                                13         1101(424/677)    REM     0.69 (0.57-0.84)    0                       58.22   0.000   79.4
  Subgroup                                                                                                                                   
   MUC1                                      11         871(338/533)     REM     0.66 (0.53-0.83)    0                       55.07   0.000   81.8
   MUC4                                      2          230(86/144)      REM     0.82 (0.55-1.22)    0.317                   2.89    0.089   65.4
  Mode of invasion (1 to 3 / 4c + 4d)                                                                                                        
  All studies                                6          745(498/247)     REM     0.58 (0.44-0.76)    0                       18.25   0.003   72.6
  Subgroup                                                                                                                                   
   MUC1                                      5          595(389/206)     REM     0.56 (0.40-0.78)    0.001                   17.42   0.002   77.0
   MUC4                                      1          150(109/41)      REM     0.67 (0.46-0.97)    0.036                   0.00    ---     ---
  Tumor size (T1 + T2 / T3 + T4)                                                                                                             
  All studies                                11         1046(660/386)    REM     0.90 (0.75-1.07)    0.236                   33.37   0.000   70.0
  Subgroup                                                                                                                                   
   MUC1                                      9          816(501/315)     REM     0.92 (0.76-1.12)    0.416                   23.21   0.003   65.5
   MUC4                                      2          230(159/71)      REM     0.79 (0.41-1.52)    0.477                   9.44    0.002   89.4

![Forest plot of association between MUC overexpression with poor clinicopathological outcome in HNC\
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Subgroup analysis stratified by different MUC subtype was performed to compare the sensitivity of MUC subtype as biomarkers. With regard to UICC stage, elevated MUC4 expression was referred to play a worse prognostic role in head and neck cancers (*n* = 1, RR = 0.56, 95% CI: 0.39-0.80, *p* = 0.002) than MUC1 (*n* = 9, RR = 0.87, 95% CI: 0.76-1.00, *p* = 0.052). For lymph node metastasis, higher MUC1 expression was related to poor prognosis (*n* = 11, RR = 1.40, 95% CI: 1.14-1.72, *p* = 0.002), but MUC4 was not (*n* = 2, RR = 1.23, 95% CI: 0.82-1.83, *p* = 0.317). Regarding mode of invasion, a worse prognostic role was strongly linked to MUC1 positivity in HNC (*n* = 5, RR = 0.56, 95% CI: 0.40-0.78, *p* = 0.001) and analogical trend was observed in aberrant MUC4 expression (*n* = 1, RR = 0.67, 95% CI: 0.46-0.97, *p* = 0.036) (Table [3](#T3){ref-type="table"}).

Sensitivity analysis {#s2_5}
--------------------

Pooled estimates of the relation of MUC overexpression to prognostic outcomes and clinicopathological parameters were not substantially altered according to the 'leave-one-out' method, demonstrating the reliability of our results (Figure [4A-4H](#F4){ref-type="fig"}).

![Sensitivity analysis based on stepwise omitting one study at a time for overall survival (OS)\
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Publication bias {#s2_6}
----------------

Analysis of survival rate and clinicopathological features demonstrated no obvious asymmetry in the funnel plots for publication bias (*p* \> 0.05) (Figure [5A-5H](#F5){ref-type="fig"}). More sensitive Egger\'s regression test confirmed these results, indicating that our pooled results had no significant publication bias.

![Begg\'s funnel plot for the evaluation of potential publication bias on overall estimate of overall survival (OS)\
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Trial sequential analysis (TSA) {#s2_7}
-------------------------------

Data from twenty trials (2046 cases) were used to investigate the reliability of MUC status as a candidate for predicting the prognosis of HNC (Figure [6A-6C](#F6){ref-type="fig"}). Using the relevance between MUC expression and cervical lymph node metastasis of HNC (including 13 trials with 1101 patients) as an example, the required information size (RIS) for adequate power was 1790 subjects. The cumulative z-curve crossed both the conventional boundary and the trial sequential monitoring boundary before reaching the RIS, indicating that our findings were conclusive and further trials seem to be unnecessary (Figure [6B](#F6){ref-type="fig"}). Similar method was applied for other groups which were not shown. On the whole, potent evidence suggested that the overexpression of MUC predicted a worse outcome.

![Trial sequential analysis of studies reporting the association between MUC protein expression and (**A**) UICC stage, (**B**) Lymph node metastasis and (**C**) Mode of invasion. The solid blue line represents the cumulative Z-curve. The dashed red line represents the trial sequential monitoring boundary. TSA indicates that no further trials are required..](oncotarget-08-96359-g006){#F6}

DISCUSSION {#s3}
==========

As revealed by the laboratorial evidence, aberrant overexpression, mislocation profiles and truncated glycans of tumor-associated MUC (TA-MUC) were commonly observed in variety of epithelial cancers. The structural and functional complexity of TA-MUC emphasizes its pivotal value in the pathogenesis and progression of cancer. However, some conflicting conclusions were reported in clinic. Although the majority of studies demonstrated that high level of MUC indicated worse clinicopathological parameters and poor prognosis, there are still a number of studies which showed the opposite conclusion \[[@R16], [@R17], [@R19]\]. Thus, a comprehensive study is urgently demanded.

To our knowledge, the present study is the first and most full-scale meta-analysis systemically exploring the possible prognostic role of MUC up-regulation in HNC. Here, 20 eligible studies including 2064 cases were combined to yield statistics, indicating that higher MUC expression was strongly related to poorer overall survival (HR = 1.83, 95% CI: 1.43-2.33, *p* = 0.000) in patients with HNC. Subgroup analysis was consistent with the pooled OS regardless of cancer type, sample size, staining cut-off value and MUC subtypes. Among patients accepted adjuvant therapy (AR and/or AC) along with surgery operation, no significant association was identified between positive MUC expression and poor OS, exhibiting a sharp contrast with the patients without AT (HR = 1.96, 95% CI: 1.51-2.53, *p* = 0.000). The discrepancy may be, partially, explained by the advanced radiotherapy technique and platinum-based therapeutic regimen for advanced HNC, achieving a significant improvement in 5-year OS \[[@R41]\]. As for western countries and ISH subgroups stratified by nationality and detecting methods respectively, no significant association was identified though a tendency was shown. This situation was possibly due to the relatively limited studies enrolled in the subgroups. As shown in Table [2](#T2){ref-type="table"}, only three qualified studies for western countries and one for ISH detecting method studies were subjected to subgroup analysis, which may affect the real results. Based on these points, large-scaled studies are still needed to strength our results in the future. Stratified by the location of tumor, aberrant expression of MUC was significantly associated with poor OS in OSCC subgroup, which exhibited a sharp contrast with the patients that suffering from LSCC. The discrepancy may be, partially, explained by the morphologic diversity between oral cavity and laryngeal regions combined with different carcinogens. The inherent biological heterogeneity induces different disease evolution process though both of them originate from epithelial cells. Varying results were noted with regard to different antibodies used for detecting MUC1 or MUC4 specificity. DF3 for MUC1 may be a more tumor-specific antibody in immunohistochemistry than others (i.e. VU4H5) in HNC especially for paraffin-embedded tissues, as the same to 8G7 for MUC4. Perhaps the best explanation for staining sensitivity differences among these antibodies may be the different binding epitopes. For example, aberrantly underglycosylated TA-MUC1 tissues may somehow mask the carbohydrate epitopes recognized by VU4H5, while still permitting reaction with DF3 which binds to peptide epitopes within the variable number of tandem repeat (VNTR) domain \[[@R42]\]. Although different survival rate were exhibited by these antibodies, the same tendency revealed that the increased expression of MUC protein was associated with unfavorable OS in patients with HNC.

Consistent with the theoretical inference, our results also demonstrated that overexpression of MUC was tightly associated with advanced TNM stage (I+II *vs*.III+IV, RR = 0.84, 95%CI: 0.73-0.97, *p* = 0.017 ), high risk of cervical lymph node metastasis (negative *vs*. positive, RR = 0.69, 95%CI: 0.57-0.84, *p* = 0.000 ) and the depth of invasion (1 to 3 *vs*. 4c+4d, RR = 0.58, 95%CI: 0.44-0.76, *p* = 0.000 ). Given that more advanced TNM stage, more positive cervical lymph node metastasis and deeper invasion are adverse prognostic features, the pooled analysis may explain why positive MUC expression was associated with poor survival rate in patients with HNC. Several studies have uncovered unique roles of the MUC on the oncogenic and pro-metastasis effects, including promoting proliferation, metabolism, angiogenesis, invasion, metastasis, epithelial to mesenchymal transition (EMT) and resistance to apoptosis \[[@R9], [@R14], [@R43]-[@R47]\]. For example, multiple studies provide direct evidence for the role of MUC1 in EMT process, which enable cancer cells acquire their invasive and metastasis potential. Notably, MUC1 can directly inhibit the expression of E-cadherin, but upregulation the EMT inducers, such as Snail, Slug, Vimentin and Twist \[[@R43]-[@R44]\]. Similarly, MUC4 can specifically potentiate phosphorylation of the receptor tyrosine kinase ErbB2, which results in up-regulation of the cyclin-dependent kinase inhibitor p27^kip^ and silence of protein kinaseB/Akt pathways \[[@R47]\]. Taken together, these mechanisms can explain the association between high MUC expression and adverse clinicalpathological features in HNC patients. Therefore, MUC can serve as a good candidate for predicting the status and prognosis of HNC, making up the deficiency of the current physical detecting methods.

Apart from the inspiring outcomes, several limitations still existed in this meta-analysis. First, the lack of unified standardized protocol and evaluation system for detecting MUC status influence the accurate estimation of prognosis for HNC. Second, the numbers of studies and patients pooled into analysis were limited due to insufficient data. Third, the missing information from negative studies which were less frequently published could lead to publication bias, although significant heterogeneity was not detected from the current analysis. Finally, despite the usage of random-effect model and subgroup analysis, some heterogeneity still existed, which may weaken our pooled conclusions.

In conclusion, despite the abovementioned limitations, our meta-analysis indicated that MUC expression was significantly associated with poorer OS, more advanced TNM stage, higher risk of cervical lymph node metastasis, and deeper invasion in patients with HNC for the first time. These findings revealed that the status of MUC could not only distinguish normal and precancerous cells but also could differentiate of a less metastatic cancer form its highly aggressive form. Therefore, patients with highly expression of MUC in HNC may need more radical treatment and rigorous monitoring, especially for those without typical symptoms or signs of metastasis. However, prospective clinical trials that are well-designed, using standardized methods, with long-term follow up, are required to verify the MUC hypothesis in HNC directly.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

This meta-analysis was conducted according to the PRISMA statement \[[@R20]\]. A systematic literature search of PubMed, Embase, and Web of Science database was performed with the following strategy: ("mucin-1" OR "muc-1" OR "episialin") AND ("oral" OR "mouth" OR "tongue" OR "gingival" OR "pharynx" OR "larynx") AND ("tumor" OR "cancer" OR "carcinoma" OR "neoplasm" OR "malignant") AND ("prognostic" OR "prognosis" OR "outcome" OR "survival") up to September 1, 2016. Citation lists of retrieved articles, including review articles, were additionally reviewed to guarantee the sensitivity of the search process.

Inclusion/exclusion criteria {#s4_2}
----------------------------

The criteria for inclusion were listed as following: (1) studies detected MUC expression by immunohistochemistry (IHC) or *in situ* hybridization (ISH) analysis in human cancer tissues; (2) sufficient information was provided to evaluate the relationship between MUC expression and clinicopathological parameters and/or cancer prognosis; (3) the hazard ratios (HRs) with 95% confidence intervals (CIs) of overall survival (OS) were provided or can be extracted from the Kaplan-Meier curves based on the method reported before \[[@R21]\].

Studies were excluded if they were: (1) reviews, case reports, meta-analyses, letters, conference abstracts without original data; (2) articles which could not extract the relevant data; (3) overlapping articles and those with duplicated data.

Data extraction {#s4_3}
---------------

The valuable data including surname of the first author, mean age, gender, cancer type, anti-body used, clinicopathological features, prognosis and other relevant data were extracted by two investigators (Lu and Liang) independently and illustrated in Table [1](#T1){ref-type="table"}. When the prognosis was only plotted as a Kaplan-Meier curve in some articles, Engauge Digital 9.3 software (from <https://sourceforge.net/projects/digitizer/>) was applied to digitize and extract the data. A joint decision was offered in the case of any disagreement.

Quality assessment {#s4_4}
------------------

The quality of included studies was assessed by two independent reviewers (Zhu and Xu) on the basis of the Newcastle-Ottawa scale (NOS) system, which is a 9-point scoring system by judging three main categories: including selection, comparability and outcome. Studies with scores≥6 were regarded as high-quality studies \[[@R22]-[@R23]\].

Statistical analysis {#s4_5}
--------------------

Pooled HR with their 95% CI was used to assess the association between MUC expression levels and the cancer prognosis (OS). Meanwhile, the impact of MUC expression on clinicopathological parameters was performed by RR with their 95% CIs. The heterogeneity among the included studies was checked by the chi-squared Q test. *P* \> 0.10 or I^2^ \< 50% indicated that the differences between the results of various studies were due to chance, and then a fixed-effect model was used. Otherwise, a random-effects model was employed. Subgroup analyses were performed to explore the source of heterogeneity. The sensitivity analysis and funnel plots were carried out to evaluate the robustness and the possible publication bias respectively. All statistical tests were performed using Stata version 12.0 (Stata Corp, College Station, TX, USA) with two-tails *p* values. A *p*-value \< 0.05 was considered to be statistically significant.

Trial sequential analysis (TSA) {#s4_6}
-------------------------------

TSA was employed to test whether the current findings were reliable and conclusive, based on diversity-adjusted threshold for statistical significance. We conducted TSA with assumptions including a plausible overall 5% risk of type I error with a power of 80%. When the cumulative z-curve crosses the trial monitoring boundary or enters the futility zone before the required power is reached, future trials are superfluous considering a sufficient level of evidence is reached \[[@R24]-[@R25]\]. Otherwise, the current evidence is insufficient for drawing a conclusion. These analyses were performed using Trial Sequential Analysis Software version 0.9 beta ([www.ctu.dk/tsa](http://www.ctu.dk/tsa)).
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